In the Phase I/II trial, CA4P will be combined with radiotherapy in a dose-escalating study of approximately 30 patients to be conducted at Mount Vernon Hospital in London. The trial protocol has been approved by the United Kingdom's health regulatory authority, the Medicines Control Agency, as well as the hospital's Institutional Ethics Committee. OXiGENE's CA4P represents an emerging class of novel tumor-starving compounds that are designed to selectively damage the vascular structure of solid tumors.
"The combination of CA4P and radiotherapy has shown a high degree of synergy in pre-clinical studies, with a 10-500 fold reduction in tumor cell survival as compared with radiotherapy treatment alone," said Fred Driscoll, OXiGENE's President and CEO. "As a result, we are particularly excited about this next phase of clinical development.
This is the second combination trial of CA4P initiated this year, and we plan to continue pursuing clinical opportunities targeting CA4P at specific cancer indications."
"In the Phase I studies of CA4P given as a single agent, there was compelling imaging data demonstrating blood flow reductions to central tumor regions," said the trial's lead investigator, Peter Hoskin, M.D., clinical oncologist at Mount Vernon Hospital. "In several pre-clinical studies, CA4P was shown to augment the tumor-killing ability of radiation,
Contact: Scott Solomon
Sharon Merrill Associates, Inc.